Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hanauske, A.-R.
Right arrow Articles by Niyikiza, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanauske, A.-R.
Right arrow Articles by Niyikiza, C.
The Oncologist, Vol. 6, No. 4, 363-373, August 2001
© 2001 AlphaMed Press

Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors

Axel-R. Hanauske, Victor Chen, Paolo Paoletti, Clet Niyikiza

Eli Lilly and Company, Indianapolis, Indiana, USA

Correspondence: Axel-R. Hanauske, M.D., Ph.D., Eli Lilly and Company, DC6065, Indianapolis, Indiana 46285, USA. Telephone: 317-433-6977; Fax 317-276-7234; e-mail: Hanauske.IND-Synergen{at}t-online.de

Pemetrexed disodium (ALIMTA®, "pemetrexed") is a novel, multi-targeted antifolate that has demonstrated promising clinical activity in a wide variety of solid tumors, including non-small cell lung, breast, mesothelioma, colorectal, pancreatic, gastric, bladder, cervix, and head and neck. Pemetrexed inhibits multiple folate-dependent enzymes involved in both purine and pyrimidine synthesis including thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase, and aminoimidazole carboxamide ribonucleotide formyltransferase. As a single agent, pemetrexed exhibits a moderate toxicity profile at a dose of 500 mg/m2 by 10-minute infusion once every 21 days with myelosuppression being the dose-limiting toxicity. Folic acid added to the diet in preclinical studies reduced toxicities while maintaining antitumor activity. Based on this observation and clinical toxicities, folic acid and vitamin B12 dietary supplementation has been recently introduced into all ongoing trials. Studies combining pemetrexed with other active chemotherapeutic agents demonstrate that these combination therapies may become important treatment regimens in a variety of cancer types. Currently, pemetrexed phase III trials are ongoing in mesothelioma and non-small cell lung cancer with future trials planned to explore this unique multitargeted antifolate.

Key Words. Multi-targeted antifolate • Thymidylate synthase inhibitor • Antimetabolite




This article has been cited by other articles:


Home page
 Ann OncolHome page
N. M. Hahn, R. T. Zon, M. Yu, F. O. Ademuyiwa, T. Jones, W. Dugan, C. Whalen, R. Shanmugam, T. Skaar, and C. J. Sweeney
A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67
Ann. Onc., December 1, 2009; 20(12): 1971 - 1976.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J-P. Sculier and D. Moro-Sibilot
First- and second-line therapy for advanced nonsmall cell lung cancer
Eur. Respir. J., April 1, 2009; 33(4): 915 - 930.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Latz, K. L. Schneck, K. Nakagawa, M. A. Miller, and C. H. Takimoto
Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients
Clin. Cancer Res., January 1, 2009; 15(1): 346 - 354.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Ohe, Y. Ichinose, K. Nakagawa, T. Tamura, K. Kubota, N. Yamamoto, S. Adachi, Y. Nambu, T. Fujimoto, Y. Nishiwaki, et al.
Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2008; 14(13): 4206 - 4212.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Nakagawa, K. Yamazaki, H. Kunitoh, T. Hida, K. Gemba, T. Shinkai, Y. Ichinose, S. Adachi, Y. Nambu, N. Saijo, et al.
Efficacy and Safety of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma: A Phase I/II Study in Japanese Patients
Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 339 - 346.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. E. Stinchcombe and M. A. Socinski
Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer
Oncologist, January 1, 2008; 13(suppl_1): 28 - 36.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. H. Takimoto, L. A. Hammond-Thelin, J. E. Latz, L. Forero, M. Beeram, B. Forouzesh, J. de Bono, A. W. Tolcher, A. Patnaik, P. Monroe, et al.
Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer
Clin. Cancer Res., May 1, 2007; 13(9): 2675 - 2683.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Malempati, H. S. Nicholson, J. M. Reid, S. M. Blaney, A. M. Ingle, M. Krailo, L. C. Stork, A. S. Melemed, R. McGovern, S. Safgren, et al.
Phase I Trial and Pharmacokinetic Study of Pemetrexed in Children With Refractory Solid Tumors: The Children's Oncology Group
J. Clin. Oncol., April 20, 2007; 25(12): 1505 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. K. Rowinsky, M. Beeram, L. A. Hammond, G. Schwartz, J. De Bono, B. Forouzesh, Q. Chu, J. E. Latz, S. Hong, W. John, et al.
A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
Clin. Cancer Res., January 15, 2007; 13(2): 532 - 539.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. H. Wilson
Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 1018 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. C. Mita, C. J. Sweeney, S. D. Baker, A. Goetz, L. A. Hammond, A. Patnaik, A. W. Tolcher, M. Villalona-Calero, A. Sandler, T. Chaudhuri, et al.
Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function
J. Clin. Oncol., February 1, 2006; 24(4): 552 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. X. Ma, P. Steen, K. M. Rowland, R. D. Niedringhaus, T. R. Fitch, J. W. Kugler, D. W. Hillman, E. A. Perez, J. N. Ingle, and A. A. Adjei
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
Ann. Onc., February 1, 2006; 17(2): 226 - 231.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Sweeney, C. H. Takimoto, J. E. Latz, S. D. Baker, D. J. Murry, J. H. Krull, K. Fife, L. Battiato, A. Cleverly, A. K. Chaudhary, et al.
Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer
Clin. Cancer Res., January 15, 2006; 12(2): 536 - 542.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. X. Ma, S. Nair, S. Thomas, S. J. Mandrekar, D. A. Nikcevich, K. M. Rowland, T. R. Fitch, H. E. Windschitl, S. L. Hillman, S. E. Schild, et al.
Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 2005; 23(25): 5929 - 5937.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. E. Huber, M. Bischof, J. Jenne, S. Heiland, P. Peschke, R. Saffrich, H.-J. Grone, J. Debus, K. E. Lipson, and A. Abdollahi
Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy
Cancer Res., May 1, 2005; 65(9): 3643 - 3655.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. Puto and J. S Garey
Pemetrexed Therapy for Malignant Pleural Mesothelioma
Ann. Pharmacother., April 1, 2005; 39(4): 678 - 683.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. V. Scagliotti, C. Kortsik, G. G. Dark, A. Price, C. Manegold, R. Rosell, M. O'Brien, P. M. Peterson, D. Castellano, G. Selvaggi, et al.
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non-Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
Clin. Cancer Res., January 15, 2005; 11(2): 690 - 696.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Xu, C. Li, A. J. Olson, and I. A. Wilson
Crystal Structure of Avian Aminoimidazole-4-carboxamide Ribonucleotide Transformylase in Complex with a Novel Non-folate Inhibitor Identified by Virtual Ligand Screening
J. Biol. Chem., November 26, 2004; 279(48): 50555 - 50565.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Pistolesi and J. Rusthoven
Malignant Pleural Mesothelioma: Update, Current Management, and Newer Therapeutic Strategies
Chest, October 1, 2004; 126(4): 1318 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. L. Misset, E. Gamelin, M. Campone, S. Delaloge, J. E. Latz, L. Bozec, and P. Fumoleau
Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors
Ann. Onc., July 1, 2004; 15(7): 1123 - 1129.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Diaz-Rubio
New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers
Oncologist, June 1, 2004; 9(3): 282 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Bajetta, L. Celio, R. Buzzoni, L. Ferrari, A. Marchiano, A. Martinetti, R. Longarini, C. Becerra, C. Ilardi, and W. John
Phase II study of pemetrexed disodium (Alimta(R)) administered with oral folic acid in patients with advanced gastric cancer
Ann. Onc., October 1, 2003; 14(10): 1543 - 1548.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Niyikiza, S. D. Baker, D. E. Seitz, J. M. Walling, K. Nelson, J. J. Rusthoven, S. P. Stabler, P. Paoletti, A. H. Calvert, and R. H. Allen
Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity from Pemetrexed Therapy
Mol. Cancer Ther., May 1, 2002; 1(7): 545 - 552.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.
Advertisement